In health economic evaluations, value added tax is commonly treated as a transfer payment. Following this argument, resources are valued equal to their net-of-tax prices in economic evaluations applying a societal perspective. In this article we argue that if there is the possibility that a new healthcare intervention may expand the healthcare budget, the social cost of input factors should be the gross-of-tax prices and not the net-of-tax prices. The rising interest in cost-benefit analysis and the use of absolute thresholds, net benefit estimates and acceptability curves in cost-effectiveness analysis makes this argument highly relevant for an appropriate use of these tools in prioritisation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Brouwer W, Rutten F, Koopmanschap M. Costing in economics evaluations. In: Drummond M, McGuire A, editors. Economic evaluation in health care. Oxford: Oxford University Press, 2001: 68–93
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press, 1978
Dasgupta AK, Pearce DW. Cost-benefit analysis: theory and practice. London: Macmillan Press Ltd, 1972
Drèze P, Stern N. Shadow prices and markets: policy reform, shadow prices and market prices. In: Layard R, Glaister S, editors. Cost-benefit analysis. Cambridge: Cambridge University Press, 1994: 59–99
Mishan EJ. Cost-benefit analysis: an informal introduction. 4th ed. London: Unwin Hyman, 1988
Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit-analysis. Soc Sci Med 1995; 41(4): 483–9
Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 2006; 62(9): 2091–100
Oliver A. Accounting for the missing opportunity costs in incremental cost-outcome analysis. Appl Health Econ Health Policy 2002; 1(4): 191–6
Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 2002; 11(1): 23–31
Drèze P, Stern N. The theory of cost-benefit analysis. In: Auerbach AJ, Feldstein M, editors. Handbook of public economics. Amsterdam: Elsevier Science Publishers, 1987: 909–89
Layard R, Glaister S. Introduction. In: Layard R, Glaister S, editors. Cost-benefit analysis. Cambridge: Cambridge University Press, 1994: 1–56
Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econo 1973; 2(2): 147–57
George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19(11): 1103–9
Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ 2003; 12(12): 1049–60
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20(3): 332–42
Hajlte K, Hjelmgren J, Johansson F, et al. Betalningsviljan for et kvalitetsjusterat levnadsar: en pilotstudie [in Swedish]. IHE e-rapport 2005: 1. Lund: Institut for Halso-och Sjukvardsekonomi, 2005
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146(4): 473–81
Buxton M. How much are health-care systems prepared to pay to produce a QALY? Eur J Health Econ 2005; 6(4): 285–7
Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7(5): 518–28
Møller F, Andersen SP, Graui P, et al. Samfundsøkonomisk vurdering af miljøprojekter. Copenhagen: Danmarks Miljøundersøgelser, Miljøstyrelsen og Skov-og Naturstyrelsen, 2000
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the contents of this review.
About this article
Cite this article
Bech, M., Christiansen, T. & Gyrd-Hansen, D. Handling Value Added Tax (VAT) in Economic Evaluations. Appl Health Econ Health Policy 5, 209–213 (2006). https://doi.org/10.2165/00148365-200605040-00003
- Economic Evaluation
- Marginal Cost
- Opportunity Cost
- Input Factor
- Shadow Price